Product Pathways - Lymphocyte Signaling
Blimp-1/PRDI-BF1 (C14A4) Rabbit mAb #9115
|9115S||100 µl (10 western blots)||---||In Stock||---|
|9115||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse||Endogenous||95-100||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IF-IC=Immunofluorescence (Immunocytochemistry)
Species predicted to react based on 100% sequence homology: Monkey.
Specificity / Sensitivity
Blimp-1/PRDI-BF1 (C14A4) Rabbit mAb detects endogenous levels of total Blimp-1/PRDI-BF1 protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val90 of human PRDI-BF1.
Western blot analysis of extracts from Karpas 620, SR and H929 cell lines using Blimp-1/PRDI-BF1 (C14A4) Rabbit mAb.
Blimp-1 (B lymphocyte-induced maturation protein) is a nuclear zinc-finger containing transcriptional repressor that is considered a master regulator of terminal B-cell development (1). The human homolog, PRDI-BF1, was identified by its ability to bind to the PRDI element on the IFN-β promoter and can inhibit virus-mediated IFN-β production (2). Expression of Blimp-1 is sufficient to drive terminal differentiation of BCL1 lymphoma cells into antibody secreting plasma cells, increasing the expression of the cell surface marker Syndecan-1 (1). In the B-cell lineage, Blimp-1 is specifically expressed in antibody-secreting cells including activated B and plasma cells. In addition, Blimp-1 has been found during macrophage differentiation (3) and in a subset of T-cells (4,5) suggesting it may play a wider role in homeostasis and differentiation (6). Mechanistically, Blimp-1 is thought to act by recruiting chromatin-modifying enzymes including histone deacetylases (7) and methyltransferases (8,9). Target genes of Blimp-1 transcriptional repression with potential roles in differentiation include c-Myc (10), CIITA (11), Pax5 (12), Spi-B, and Id3 (13).
- Turner, C.A. et al. (1994) Cell 77, 297-306.
- Keller, A.D. and Maniatis, T. (1991) Genes Dev 5, 868-79.
- Chang, D.H. et al. (2000) Nat Immunol 1, 169-76.
- Kallies, A. et al. (2006) Nat Immunol 7, 466-74.
- Martins, G.A. et al. (2006) Nat Immunol 7, 457-65.
- Kallies, A. and Nutt, S.L. (2007) Curr Opin Immunol 19, 156-62.
- Yu, J. et al. (2000) Mol Cell Biol 20, 2592-603.
- Gyory, I. et al. (2004) Nat Immunol 5, 299-308.
- Ancelin, K. et al. (2006) Nat Cell Biol 8, 623-30.
- Lin, Y. et al. (1997) Science 276, 596-9.
- Chen, H. et al. (2007) Mol Immunol 44, 1461-70.
- Lin, K.I. et al. (2002) Mol Cell Biol 22, 4771-80.
- Shaffer, A.L. et al. (2006) Immunol Rev 210, 67-85.
- Smith, M.A. et al. (2010) J Immunol 185, 6058-67. Applications: Chromatin IP, Western Blotting.
- Desai, S. et al. (2010) Mol Cancer Res 8, 907-18. Applications: Western Blotting.
- Cubedo, E. et al. (2011) FEBS J 278, 3065-75. Applications: Chromatin IP.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
U.S. Patent No. 5,675,063.
DRAQ5® is a registered trademark of Biostatus Limited.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.